Oncolytic virus-based hepatocellular carcinoma treatment:Current status,intravenous delivery strategies,and emerging combination therapeutic solutions  

作　　者：Xinguo Li Xiaonan Sun BingyuanWang Yiling Li Jing Tong 

机构地区：[1]The First Hospital of China Medical University,Shenyang 110001,China [2]The 4th People’s Hospital of Shenyang,Shenyang 110031,China

出　　处：《Asian Journal of Pharmaceutical Sciences》2023年第1期4-26,共23页亚洲药物制剂科学（英文）

基　　金：by the National Natural Science Foundation of China(No.81700453).

摘　　要：Current treatments for advanced hepatocellular carcinoma(HCC)have limited success in improving patients’quality of life and prolonging life expectancy.The clinical need for more efficient and safe therapies has contributed to the exploration of emerging strategies.Recently,there has been increased interest in oncolytic viruses(OVs)as a therapeutic modality for HCC.OVs undergo selective replication in cancerous tissues and kill tumor cells.Strikingly,pexastimogene devacirepvec(Pexa-Vec)was granted an orphan drug status in HCC by the U.S.Food and Drug Administration(FDA)in 2013.Meanwhile,dozens of OVs are being tested in HCC-directed clinical and preclinical trials.In this review,the pathogenesis and current therapies of HCC are outlined.Next,we summarize multiple OVs as single therapeutic agents for the treatment of HCC,which have demonstrated certain efficacy and lowtoxicity.Emerging carrier cell-,bioengineered cell mimetic-or nonbiological vehicle-mediated OV intravenous delivery systems in HCC therapy are described.In addition,we highlight the combination treatments between oncolytic virotherapy and other modalities.Finally,the clinical challenges and prospects of OV-based biotherapy are discussed,with the aim of continuing to develop a fascinating approach in HCC patients.

关 键 词：Oncolytic viruses(OVs) OV intravenous delivery systems Combination treatments Advanced hepatocellular carcinoma (HCC) Pexa-Vec 

分 类 号：R735.7[医药卫生—肿瘤]